Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer
R Chadar, P Kesharwani - International Journal of Pharmaceutics, 2021 - Elsevier
Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …
Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer
R Chadar, P Kesharwani - International journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …
Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer.
R Chadar, P Kesharwani - International Journal of Pharmaceutics, 2021 - europepmc.org
Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …